Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AZTR | US
0.01
3.33%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.22
0.21
0.22
0.21
Azitra Inc a pre-clinical biopharmaceutical company focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12 a genetically modified strain of S. epidermidis for treating Netherton syndrome a skin disease; ATR-04 a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01 an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris a skin disease. The company was incorporated in 2014 and is based in Branford Connecticut.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
41.0%1 month
50.2%3 months
156.6%6 months
135.7%0.01
-
2.42
0.42
0.19
-0.39
10.02
-
-10.12M
1.68M
1.68M
-
-35.47K
-
-95.60
-222.30
0.78
3.18
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.08
Range3M
0.28
Rel. volume
0.24
Price X volume
79.36K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.2299 | 1.59M | 3.19% | n/a | 0.77% |
| RedHill Biopharma Ltd | RDHL | Biotechnology | 1.025 | 1.31M | -0.49% | n/a | 65.80% |
| ADTX | ADTX | Biotechnology | 0.2826 | 1.19M | -2.35% | n/a | 122.46% |
| ERNA | ERNA | Biotechnology | 0.1917 | 1.04M | 0.37% | n/a | -577.12% |
| Phio Pharmaceuticals Corp | PHIO | Biotechnology | 1.19 | 1.02M | -3.25% | n/a | 0.00% |
| Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 0.6269 | 944.73K | 1.93% | n/a | 0.00% |
| Evofem Biosciences Inc | EVFM | Biotechnology | 0.0087 | 872.86K | 3.57% | 0.00 | 0.00% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.1361 | 745.92K | -11.62% | n/a | 268.29% |
| Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 0.69 | 720.99K | 0.10% | n/a | 0.00% |
| Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 0.1596 | 692.98K | 0.44% | n/a | 4.18% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.39 | 0.53 | Cheaper |
| Ent. to Revenue | 10.02 | 3,967.00 | Cheaper |
| PE Ratio | 0.01 | 41.03 | Cheaper |
| Price to Book | 2.42 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 156.59 | 72.80 | Riskier |
| Debt to Equity | 0.42 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 1.68M | 3.66B | Emerging |